Results 131 to 140 of about 105,476 (242)

Pharmacological inhibition of hydroxysteroid 11‐beta dehydrogenase type 1 (11‐βHSD1) after myocardial infarction preserves cardiac function in a translational mini‐pig model

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Plasma glucocorticoids increase acutely after MI, thereafter tissue levels are amplified selectively within cells expressing 11‐ßhydroxysteroid dehydrogenase type 1 (11‐ßHSD1) that regenerates active glucocorticoids from circulating metabolites.
Sara Al Disi   +19 more
wiley   +1 more source

B-type natriuretic peptide changes and left ventricular remodeling dynamics in heart failure with reduced ejection fraction. [PDF]

open access: yesFront Cardiovasc Med
Romero E   +8 more
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska   +2 more
wiley   +1 more source

Disproportional ventilatory response to incremental exercise in individuals with cerebral palsy

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Individuals with cerebral palsy demonstrate a disproportionate ventilatory response during incremental exercise. Compared with typically developing peers, respiratory frequency increases earlier and at comparable exercise intensities, contributing to higher perceived exertion and reduced ventilatory efficiency. At task failure, respiratory frequency is
Linnéa Corell   +14 more
wiley   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen   +7 more
wiley   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy